The global enzyme linked immunosorbent assay (ELISA) market is witnessing significant growth owing to the wide range of applications in disease testing and diagnosis. ELISA is a plate-based assay technique used to detect the presence of antibodies and proteins in samples by using biological molecules called antigens or immunoglobulins. In ELISA, antigens are bound to a solid surface and then treated with biological fluids or samples suspected of containing antibodies. The antibodies, if present, bind specifically to the antigens affixed to the solid surface. Detection of bound antigen-antibody complexes provides an indirect measure of antigen in suspect samples.

Enzyme Linked Immunosorbent Assay Market Demand has been commonly used to detect the presence of disease-associated proteins in serum and diagnose conditions such as HIV, hepatitis, Lyme disease, and mycobacterial infections.

Enzyme Linked Immunosorbent Assay (ELISA) Market is estimated to be valued at US$ 2,016.1 million in 2022 and is expected to exhibit a CAGR of 5.1% during the forecast period (2022-2030).

Key players operating in the enzyme linked immunosorbent assay market are Thermo Fisher Scientific, BD biosciences, Roche diagnostics,bio-rad laboratories, and Agilent technologies.

Key Takeaways

Key players operating in the enzyme linked immunosorbent assay market are focusing on new product launches and strategic collaborations to expand their geographical presence. For instance, in August 2022, Thermo Fisher Scientific launched two new ELISAs to aid the diagnosis of active tuberculosis disease.

Get More Insights On Enzyme Linked Immunosorbent Assay Market